Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

102.02USD
2 Dec 2016
Change (% chg)

$2.09 (+2.09%)
Prev Close
$99.93
Open
$100.22
Day's High
$104.20
Day's Low
$98.94
Volume
400,413
Avg. Vol
488,246
52-wk High
$118.49
52-wk Low
$55.00

INCY.OQ

Chart for INCY.OQ

About

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $20,364.43
Shares Outstanding(Mil.): 188.39
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): 144.64 42.21 29.87
EPS (TTM): 0.75 -- --
ROI: 14.48 -1.09 14.95
ROE: 65.63 -2.39 16.29

BRIEF-Baricitinib demonstrates early response compared to placebo

* Baricitinib demonstrates early response compared to placebo and significant improvement compared to Adalimumab in patient-reported outcomes

Nov 14 2016

BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3

* Eli lilly -new analyses of phase 3 trials show improvements in rheumatoid arthritis symptoms following treatment with Baricitinib Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Incyte Q3 earnings per share $0.19

* Sees fy research and development expenses $570 million-$580 million

Nov 01 2016

BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial

* Additional phase 1 data from ECHO-202 reinforce durability of response in patients with treatment-naive advanced or metastatic melanoma treated with epacadostat in combination with keytruda (pembrolizumab)

Oct 07 2016

BRIEF-GrowPros announces name change to Tetra Bio-Pharma Inc.

* GrowPros announces name change to Tetra Bio-Pharma Inc., the closing of a non-brokered private placement, and extends warrants Source text for Eikon: Further company coverage: ;))

Sep 28 2016

BRIEF-Incyte corp - Epacadostat in combination with Pembrolizumab was well-tolerated

* Updated Phase 1 data reinforce the clinical profile of Epacadostat in combination with Keytruda (pembrolizumab)

Sep 28 2016

BRIEF-Immunovaccine announces dosing of first patient in Phase 1B clinical trial for DPX-Survivac

* Survivac in combination with Incyte's IDO1 enzyme inhibitor Epacadostat Source text for Eikon: Further company coverage:

Sep 08 2016

BRIEF-Incyte reported Q2 EPS $0.18

* Quarter financial results and updates key clinical programs

Aug 09 2016

Old pharma sees new profit cure in cancer drugs

Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

BRIEF-FDA grants breakthrough therapy designation for Incyte's Ruxolitinib

* FDA grants breakthrough therapy designation for Incyte's Ruxolitinib (Jakafi) in acute Graft-Versus-Host disease (GVHD) Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Jun 23 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $31.63 +0.17
Abbott Laboratories (ABT.N) $37.90 +0.30
Amgen, Inc. (AMGN.OQ) $144.01 +1.62
Biogen Inc (BIIB.OQ) $297.19 +1.41
Roche Holding Ltd. (ROG.S) CHF220.60 -1.60
Roche Holding Ltd. (RO.S) CHF224.60 -1.10
Sanofi SA (SASY.PA) €75.30 +0.14

Earnings vs. Estimates